课题基金 / 基金详情

项目摘要

项目成果

STEVEN P STRATTON的其他基金

相似基金

相关文献

中文摘要
翻译
9.2方案审查和监测系统(PRMS) 亚利桑那州癌症中心的方案审查和监测系统促进了我们的科学审查 委员会(SRC),这是配备了适当的教师和科学代表在所有学科, 包括但不限于医学血液学/肿瘤学、外科肿瘤学、妇科肿瘤学、放射学 肿瘤学、儿科血液学/肿瘤学。其他医学亚专业,癌症化学预防,以及, 与临床和基础科学合作者的临床研究也包括在内。 AZCC SRC的主要职责包括: 审查所有新的假设产生的诊断或治疗性质的介入方案, 以及涉及患者、患者样本或患者记录的纵向人群研究 由AZCC成员进行,以确保临床研究的最高科学质量, IRB提交。 审查AZCC成员进行的方案的持续进展,以最大限度地提高科学有效性, 确保及时有效的执行。 - 评估符合条件的协议在利用AZCC共享资源/服务方面的优点, 客观的科学评论。 在AZCC中促进协议实施和转化研究的统一标准 参与癌症治疗和护理的各个学科的研究人员。 无论方案类型如何,均不得向 机构IRB,直至获得SRC批准。SRC行动和批准将伴随IRB提交。在 特殊情况下,经SRC书面许可,可允许同时进行IRB审查 董事长
英文摘要
9.2 Protocol Review and Monitoring System (PRMS) The Protocol Review and Monitoring System at the Arizona Cancer Center facilitates the our Scientific Review Committee (SRC), which is staffed with appropriate faculty and scientific representation in all disiciplines, to include but not be limited to medical hematology/oncology, surgical oncology, gynecologic oncology, radiafion oncology, pediatric hematology/oncology. Other medical subspecialities, cancer chemoprevention, and, translationals studies with clinical and basic science collaborators are also covered. The primary responsibilities of the AZCC SRC include the following: ¿ Review of all new hypothesis-generated interventional protocols of diagnostic or therapeutic nature as well as longitudinal population-based studies involving patients, patient samples, or patient records conducted by AZCC members to ensure the highest scientific quality of clinical research in advance of IRB submission. ¿ Review ongoing progress of protocols conducted by AZCC members to maximize scientific validity, assure timely and effective performance. - ¿ Evaluate the merit of eligible protocols for utilization of AZCC shared resources/services based upon objective scientific review. ¿ Promote unified standards for protocol implementation and translational research among AZCC investigators of various disciplines involved in cancer treatment and care. Regardless of the protocol type, no clinical research study eligible for SRC review can be submitted to the institutional IRB until SRC approval is granted. SRC actions and approval will accompany IRB submissions. In exceptional circumstances, concurrent IRB review may be allowed with written permission from the SRC Chairman.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Translational Studies and Clinical Pharmacology of New Drugs for Chemoprevention
  • 批准号:
    8689936
  • 项目类别:
  • 资助金额:
    $5.18万
  • 财政年份:
    2013
  • 负责人:
    STEVEN P STRATTON
  • 依托单位:
Core--Drug Development
  • 批准号:
    6991771
  • 项目类别:
  • 资助金额:
    $20.82万
  • 财政年份:
    2004
  • 负责人:
    STEVEN P STRATTON
  • 依托单位:
MOLECULAR CHEMOPREVENTION MECHANISMS OF TEA POLYPHENOLS
  • 批准号:
    6378120
  • 项目类别:
  • 资助金额:
    $11.01万
  • 财政年份:
    2000
  • 负责人:
    STEVEN P STRATTON
  • 依托单位:
MOLECULAR CHEMOPREVENTION MECHANISMS OF TEA POLYPHENOLS
  • 批准号:
    6845717
  • 项目类别:
  • 资助金额:
    $5.66万
  • 财政年份:
    2000
  • 负责人:
    STEVEN P STRATTON
  • 依托单位:
海外基金